LEXINGTON, Mass., May 17, 2018 /PRNewswire/ -- Agenus
Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies, cancer vaccines, and adoptive cell
therapies1, announced that data on its proprietary
AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) antibodies have
shown consistent clinical activity with a number of partial
responses, stable disease and currently, one complete
responder. Updated data on these agents will be presented at
the 2018 American Society of Clinical Oncology (ASCO) Annual
Meeting, in Chicago June 1-5. Agenus recently announced the launch of
a combination study with AGEN1884 and AGEN2034 in second-line
cervical cancer (NCT03495882), designed as a potential pivotal
program to support a rapid path to BLA.
![Agenus Logo Agenus Logo](https://mma.prnewswire.com/media/403578/Agenus_Logo.jpg)
"Our strategy is built on innovation and speed, critical
elements for success in I-O. Our lead CTLA-4 and PD-1 are advancing
rapidly in the clinic with more than 100 patients treated," said
Garo Armen, PhD, Chairman and CEO of
Agenus. "AGEN1884 is the most advanced anti-CTLA-4 antibody
(of the same IgG1 subclass as Yervoy®) in the clinic with the
potential to be the second to market. We are pleased to
report that after the first 100 patients have been treated, our
antibodies are clinically active and are advancing in combination
in second-line cervical cancer, an indication for which patients
have no effective therapies, and presents a path to BLA
filing."
Poster Presentation Details:
- Clinical data from AGEN2034 trial
Poster Title: Phase 1/2
Open-Label, Multiple Ascending Dose Trial of AGEN2034, an anti-PD-1
Monoclonal Antibody, in Advanced Solid Malignancies: Results of
Dose Escalation
Session: Developmental
Therapeutics—Immunotherapy
Abstract Number: 3086
Poster Board Number: 300
Session Date: Monday, June 4,
2018
Location: Hall A
Session Time: 8:00 AM to 11:30
AM
- Clinical data from AGEN1884 trial
Poster Title: Phase 1
Open-Label, Ascending Dose Trial of AGEN1884, an anti-CTLA-4
Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection
for Combination with PD-1 Blockade
Session: Developmental
Therapeutics—Immunotherapy
Abstract Number: 3075
Poster Board Number: 289
Session Date: Monday, June 4,
2018
Location: Hall A
Session Time: 8:00 AM to 11:30
AM
At ASCO, Agenus will provide an update on the specifics of
clinical responses as well as pharmacologic and pharmacodynamic
responses of AGEN1884 and AGEN2034 in patients with advanced and
refractory solid tumors. Data from the combination study will be
presented at future medical meetings.
Abstracts and posters will become available on the Company's
website
at http://agenusbio.com/technology/publications/ following
the poster sessions.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please
visit www.agenusbio.com; information that may be important to
investors will be routinely posted on our website.
Forward-Looking Statements
This press
release contains forward-looking statements that are made pursuant
to the safe harbor provisions of the federal securities laws,
including statements regarding Agenus' planned presentations of
clinical data at ASCO, the planned presentation of additional data
at future medical meetings, the potential for AGEN1884 to be the
second-to-market CTLA-4 antibody, the potential for Agenus'
combination trial in second-line cervical cancer to be a pivotal
trial with a rapid path to BLA, and other clinical trial plans and
activities. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other
than to the extent required by law. All forward-looking statements
are expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of
Agenus
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-clinical-data-on-lead-programs-at-asco-2018-300650544.html
SOURCE Agenus Inc.